Original Article
Mucormycosis: analysis of 310 cases reported in China from 1980 to 2020
Sun Junping, Wang Jianxin, Zhang Mingyue, Han Xinjie, Zhang Xingang
Published 2022-02-20
Cite as Int J Respir, 2022, 42(4): 279-284. DOI: 10.3760/cma.j.cn131368-20211202-00891
Abstract
ObjectiveTo analyze the epidemiology, predisposing factors, and prognosis of mucormycosis, which were reported from 1980 to 2020 in China.
MethodsThis was a cross-sectional study.A total of 310 cases of mucormycosis reported from 1980 to 2020 were collected by using the following six databases: the Chinese National Knowledge Infrastructure, Wanfang Data, VIP Information for Biomedical Engineering and Clinical Medicine, China Hospital Knowledge Database, China Biology Medicine Disc, and Chinese Medical Association Full-text Database.The data collected include age, gender, onset time, underlying diseases, infection site, diagnostic method, treatment method and prognosis of the patients, and statistical analysis of the epidemiology was performed.
ResultsA total of 310 cases of mucormycosis were reported over the 40-year period with a mortality rate of 42.9%.The reported incidence showed an increasing trend annually.Among the cases, 59.7% had a long-term history of broad-spectrum antibiotic application, and this proportion increased annually.Diabetes was a common underlying disease, accounting for 33.5% of the cases, and was an independent risk factor for the death of patients with mucormycosis (OR=2.22, 95%CI: 1.02-4.83). Pulmonary infection was common and found in 41.0% of all patients (127/310), with a mortality rate of 50.4% (64/127). Sinus infections accounted for 21% of cases, with a mortality rate of 41.5%.Amphotericin B and its liposomes reduced the risk of death in the patients (OR=0.33, 95% CI: 0.17-0.64). Surgery also reduced the mortality rate (OR=0.14, 95%CI: 0.06-0.32).
ConclusionsIn the recent years, the incidence of mucormycosis has significantly increased.The extensive application of broad-spectrum antibiotics, diabetes and the use of hormones were risk factors for mucormycosis.The mortality rate was affected by a variety of factors, including the underlying diseases, infection site and treatment.Surgery and amphotericin B with its liposomes were effective treatments that can improve the prognosis and reduce mortality in patients with mucormycosis.
Key words:
Mucormycosis; Diabetes; Lung; Sinus; Amphotericin B; Surgery
Contributor Information
Sun Junping
Department of Respiratory and Critical Care Medicine, the Eighth Medical Center of PLA General Hospital, Beijing 100193, China
Wang Jianxin
Department of Respiratory and Critical Care Medicine, the Eighth Medical Center of PLA General Hospital, Beijing 100193, China
Zhang Mingyue
Department of Respiratory and Critical Care Medicine, the Eighth Medical Center of PLA General Hospital, Beijing 100193, China
Han Xinjie
Department of Respiratory and Critical Care Medicine, the Eighth Medical Center of PLA General Hospital, Beijing 100193, China
Zhang Xingang
Department of Respiratory and Critical Care Medicine, the Eighth Medical Center of PLA General Hospital, Beijing 100193, China
